Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sevelamer - Sanofi

Drug Profile

Sevelamer - Sanofi

Alternative Names: PB 94; Phosblock; Renagel

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genzyme Corporation
  • Developer Chugai Pharmaceutical; Kyowa Hakko Kirin; Kyowa Kirin; Sanofi
  • Class Antihyperglycaemics; Chlorinated hydrocarbons; Epoxy compounds; Hyperphosphataemia therapies; Polyamines; Small molecules
  • Mechanism of Action Chelating agents; Glucagon-like peptide-1 receptor antagonists; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for clinical-Phase-Unknown development in Type-2-diabetes-mellitus(In the elderly, In adults) in Denmark (PO, Suspension)
  • 27 Sep 2021 Efficacy data from SeveX clinical trial in Type 2 diabetes mellitus presented at 57th Annual Meeting of the European Association for the Study of Diabetes (EASD-2021)
  • 01 Sep 2021 Sanofi completes SeveX clinical trial in Type 2 diabetes mellitus (In adults, In elderly) in Denmark (PO) (NCT03739268)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top